Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Paclitaxel trevatide - Angiochem

Drug Profile

Paclitaxel trevatide - Angiochem

Alternative Names: ANG-1005; Angiopep peptide + paclitaxel conjugate – Angiochem; Angiopep-2 paclitaxel conjugate - Angiochem; GRN-1005; Paclitaxel peptide vector conjugate - Angiochem; Paclitaxel-AngioPep1-conjugate-Angiochem; SNG 1005

Latest Information Update: 09 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AngioChem
  • Class Antineoplastics; Drug conjugates; Paclitaxels; Peptides
  • Mechanism of Action Mitosis inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Brain metastases; Glioblastoma; Glioma

Most Recent Events

  • 05 Aug 2019 Innovent Biologics enters into a collaboration agreement with Shenogen Pharma Group for Cancer (Combination therapy, Late-stage disease)
  • 29 May 2019 The National Medical Products Administration approves an IND for a phase II/III trial in Brain metastases (in patients with HER2-negative breast cancer) in China (9272559; 9272205)
  • 29 May 2019 Shenogen Pharma Group plans a phase II/III trial in Brain metastases (in patients with HER2-negative breast cancer) in China (9272559; 9272205)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top